logo
Waymark Signal Achieves 85% Accuracy in Predicting Medicaid Care Gaps, Study in npj Digital Medicine Shows

Waymark Signal Achieves 85% Accuracy in Predicting Medicaid Care Gaps, Study in npj Digital Medicine Shows

Peer-reviewed research demonstrates dramatic improvement in identifying and closing quality gaps for Medicaid patients, outperforming current methods by 35 percentage points
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 4, 2025 / Healthcare organizations nationwide face a critical challenge: how to effectively deploy limited staff to close quality measure gaps among patients receiving Medicaid. With health plans facing financial penalties for poor quality performance and providers under value-based contracts unable to reach vulnerable patients through traditional methods, many resort to ineffective and untargeted mass outreach campaigns - helping fewer than 8% of eligible patients.
A new peer-reviewed study from Waymark published in Nature's npj Digital Medicine offers a solution. Signal for Quality Improvement, the company's newest predictive analytics technology, identifies with 85% accuracy which Medicaid patients will benefit most from proactive community-based outreach-enabling care teams to prioritize and target patients who need additional support to close gaps in care and improve quality performance.
'Healthcare organizations know that community-based outreach works, but they've been unable to identify and prioritize who will benefit most from these limited resources,' said Dr. Sadiq Y. Patel, lead author of the study and Vice President of Data Science and Artificial Intelligence (AI) for Waymark. 'The challenge isn't just identifying patients with open gaps-it's distinguishing between those who will close gaps on their own versus those who need proactive outreach and support. By incorporating social determinants of health data alongside clinical factors, Signal for Quality Improvement enables care teams to more efficiently prioritize outreach to the patients who need it most.'
The study analyzed data from over 14 million Medicaid beneficiaries across 25 states and Washington D.C.. Researchers found that Signal for Quality Improvement achieved 85% accuracy in predicting which patients would miss nine nationally adopted quality measures, as defined by the Healthcare Effectiveness Data and Information Set (HEDIS) developed by the National Committee for Quality Assurance (NCQA). Model simulations showed that using this predictive prioritization to guide outreach would result in a 35 percentage point improvement in helping patients close care gaps compared to traditional, non-predictive methods used by most healthcare organizations, such as alphabetical calling or birthday reminders.
Signal for Quality Improvement is the latest addition to the company's proprietary Waymark SignalTM platform, which also includes Signal for Rising Risk. A 2024 peer-reviewed study published in Nature Scientific Reports demonstrated that Signal for Rising Risk predicts patients at risk for future avoidable emergency department (ED) and hospital visits with greater than 90% accuracy. Signal for Quality Improvement builds on this technology by enabling health plans and providers to identify which patients will most benefit from proactive outreach to close quality gaps and improve HEDIS performance.
'Healthcare organizations face significant financial penalties when quality metrics are poor, but current outreach methods are remarkably inefficient,' said Dr. Sanjay Basu, Co-founder and Head of Clinical at Waymark and senior author of the study. 'Signal for Quality Improvement represents a fundamental shift toward evidence-based patient outreach that can improve both health outcomes and resource allocation for the 80 million Americans covered by Medicaid.'
The study found that incorporating social determinants of health data not only improved predictive accuracy, but also eliminated pre-existing racial disparities in prediction performance between Black and White patients across four quality measures. 'This paper addresses a persistent challenge in healthcare: efficiently reaching patients who need care most,' said Dr. Michael L. Barnett, study co-author and Professor at Brown School of Public Health. 'The combination of high predictive accuracy with a thoughtful approach that minimized racial bias offers a pathway toward more equitable healthcare delivery.'
Waymark works with health plans and primary care providers to deliver community-based early interventions to patients receiving Medicaid. The company's local care teams use the Waymark Signal platform to identify and support patients who are at risk of avoidable ED and hospital visits or have open gaps in care. A 2024 peer-reviewed study published in NEJM Catalyst found that Waymark reduced all-cause hospital and ED visits by 22.5% for rising risk patients, and improved care quality by an average of 11.8 absolute percentage points across seven quality measures in its first year of service.
The full article titled " Predicting Quality Measure Completion Among 14 Million Low-Income Patients Enrolled in Medicaid " was published in npj Digital Medicine, a peer-reviewed journal published by Nature. The authors were Sadiq Y. Patel MSW PhD of Waymark, Michael L. Barnett MD of Brown School of Public Health, and Sanjay Basu MD PhD of Waymark.
About Waymark
Waymark is a public benefit company dedicated to improving access and quality of care for people receiving Medicaid. We partner with health plans and primary care providers-including health systems, federally qualified health centers (FQHCs), and independent practices-to provide community-based care to people enrolled in Medicaid. Our local teams of community health workers, pharmacists, therapists and care coordinators use proprietary data science technologies to deliver early interventions to hard-to-reach patient populations. Waymark's peer-reviewed research has been published in leading journals including the New England Journal of Medicine (NEJM) Catalyst, Nature Scientific Reports, and Journal of the American Medical Association (JAMA)-demonstrating measurable improvements in health outcomes and cost savings for Medicaid populations. For more information, visit www.waymarkcare.com.
Contact Information
Iman Rahim
Communications
[email protected]
SOURCE: Waymark
press release
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

iCRYO's CEO and CAO to Join Vitality Business Summit 2025 as Featured Speakers
iCRYO's CEO and CAO to Join Vitality Business Summit 2025 as Featured Speakers

Yahoo

time18 minutes ago

  • Yahoo

iCRYO's CEO and CAO to Join Vitality Business Summit 2025 as Featured Speakers

DALLAS, Aug. 6, 2025 /PRNewswire/ -- iCRYO, a leading health, wellness, and longevity franchise, is excited to announce that its CEO and Co-Founder, Kyle Jones, and Chief Administrative Officer (CAO), Scott Briner, will be featured speakers at the Vitality Business Summit 2025. The summit, scheduled for October 3-5, 2025, at the Hilton DFW Lakes Executive Conference Center in Dallas, Texas, is organized and hosted by brothers Chris and Brad Himel of Himel Health, longtime consultants for health and wellness clinics. Leveraging their network, they are bringing together brand entrepreneurs, clinic owners, and other health enthusiasts to shape the future of health and wellness. Emphasizing practical solutions over passing trends, The Vitality Business Summit promises to equip attendees with the tools to build scalable, purpose-driven businesses. Kyle W. Jones, as a pioneer in cryotherapy and holistic wellness going back to 2015, will join a host of other accomplished leaders in the industry, including acclaimed speaker and author Tim Storey, motivational speaker Jenn Drummond, BrainTap founder Dr. Patrick Porter, business coach Raquel Diehm, and OxyHealth CEO Dr. Mayur Patel, to name a few. "I'm thrilled to speak at the Vitality Business Summit and share the strategies that have fueled iCRYO's growth while keeping wellness accessible," said Jones. "At the same time, this event is a catalyst for change, with innovation and adoption moving ever faster in this space. This summit offers us a chance to keep our finger on the pulse and connect with other professionals building businesses that will make a lasting impact." iCRYO's CAO and former hospital CEO Scott Briner echoed Jones' thoughts, adding, "I'm honored to join Kyle as a speaker and represent iCRYO at the Vitality Business Summit this fall. We've developed what we believe is the new industry-standard for medical care in a retail environment, and we're proud to share it with the world any chance we get. However, we're always looking to learn, grow, and improve iCRYO's service and offerings, and this event gives us that chance." The summit caters to a diverse audience, from solo practitioners to multi-unit clinic owners, offering unparalleled opportunities to learn sales and marketing frameworks used by successful clinics, network with world-class experts, explore dozens of vendors showcasing the latest in wellness modalities and therapies, develop a tailored growth plan, and create lasting partnerships. Early Bird pricing offers up to 50% off General Admission and 33% off VIP tickets, which include a VIP Lunch with speakers on Sunday. Attendees are encouraged to secure their spots now as both General Admission and VIP tickets are going fast with these early bird offers. Event Details: Date: October 3-5, 2025 Location: Hilton DFW Lakes Executive Conference Center, Dallas, Texas Tickets: Available at About iCRYO Founded in 2015, iCRYO's mission is to elevate the quality of life of its team members, guests, and franchisees by providing affordable, professional, and convenient personal health services while raising the standard as a global wellness brand. To learn more about its services, locations, and franchise opportunities, visit iCRYO Media Contact Robbie JenkinsDirector of View original content to download multimedia: SOURCE iCRYO Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

RFK Jr.'s slander of mRNA technology will harm Americans
RFK Jr.'s slander of mRNA technology will harm Americans

Washington Post

time21 minutes ago

  • Washington Post

RFK Jr.'s slander of mRNA technology will harm Americans

Robert F. Kennedy Jr.'s decision to cancel almost $500 million in contracts for projects to develop vaccines using mRNA technology underscores perhaps the greatest harm that he might inflict on the nation with his anti-vaccine ideology. The disparagement of existing immunizations by the health and human services secretary is dangerous on its own, in that it might persuade people to forego recommended shots and reduce herd immunity against diseases. But potentially even worse are the impacts that will be harder to see: the diseases that public health officials won't be able to fight because of the lifesaving innovations he is cutting short. Kennedy's resistance against mRNA vaccines is without evidence. In fact, the technology — which instructs the body's cells to produce a harmless bit of virus that is then used to train the immune system, as opposed to using weakened or dead versions of a virus — delivered arguably the most important achievement of President Donald Trump's first term: the production of effective vaccines against the novel coronavirus within the span of a few months. Such speed was practically unheard-of in biomedical research. Thanks to the urgency created by Operation Warp Speed, the federal government was able to mount an impressive vaccination rollout that boosted the population's immunity to the coronavirus just when it was needed. As with any medical treatment, these vaccines were not perfect. In very rare instances among adolescents, they resulted in a serious side effect known as myocarditis, or inflammation of the heart muscle. Their effectiveness also waned over time as the coronavirus mutated, as is the case with vaccines for other respiratory diseases. But there can be no doubt: These vaccines saved millions of lives. Kennedy absurdly claimed in a video statement that 'mRNA vaccines don't perform well against viruses that infect the upper respiratory tract.' He further claimed that a single mutation in a virus can render vaccines 'ineffective.' He even went so far as to argue that this effect 'encourages' mutations and could 'prolong' a pandemic. This is just plain wrong, as the covid pandemic demonstrated. The effectiveness of mRNA coronavirus vaccines might have diminished over time, but they continued to protect people against severe illness over the course of multiple strains. In fact, the Centers for Disease Control and Prevention continued to recommend the shots for vulnerable populations for that reason, and manufacturers updated boosters to combat new strains. Giving up on this game-changing technology will slow down scientific innovation, leaving Americans more vulnerable to diseases. Kennedy just canceled or altered 22 mRNA projects that were supported by the Biomedical Advanced Research and Development Authority. On the chopping block are vaccine developments for several respiratory illnesses. That includes a project to defend the country against the H5N1 bird flu virus, which scientists warn could spiral into a deadly pandemic if someone contracts it while also infected with the seasonal flu virus. And that's just the beginning. Researchers are eager to deploy mRNA technology against a slew of other hard-to-tackle pathogens, from hepatitis C to HIV to malaria. There are even efforts to use this approach to activate the immune system to attack cancer cells and to treat other genetic diseases. Some scientists have suggested this research could also be essential for national security, as it might help defend against attacks from biological weapons. Calling Kennedy's latest actions shortsighted understates the gravity of his slander. Americans will bear the cost of his rejection of science.

Fear Of AGI Is Driving Harvard And MIT Students To Drop Out
Fear Of AGI Is Driving Harvard And MIT Students To Drop Out

Forbes

time21 minutes ago

  • Forbes

Fear Of AGI Is Driving Harvard And MIT Students To Drop Out

W hen Alice Blair enrolled in the Massachusetts Institute of Technology as a freshman in 2023, she was excited to take computer science courses and meet other people who cared about making sure artificial intelligence is developed in a way that's good for humanity. Now she's taking a permanent leave of absence, terrified that the emergence of 'artificial general intelligence,' a hypothetical AI that can perform a variety of tasks as well as people, could doom the human race. 'I was concerned I might not be alive to graduate because of AGI,' said Blair, who is from Berkeley, California. 'I think in a large majority of the scenarios, because of the way we are working towards AGI, we get human extinction.' She's lined up a contract gig as a technical writer at the Center for AI Safety, a nonprofit focused on AI safety research, where she helps with newsletters and research papers. Blair doesn't plan to head back to MIT. 'I predict that my future lies out in the real world,' she said. Blair's not the only student afraid of the potentially devastating impact that AI will have on the future of humanity if it becomes sentient and decides that people are more trouble than they're worth. 'Extinction-level' risk is possible given how fast AI is being developed, according to a 2024 U.S. Department of State-commissioned report. Efforts to build AI with safeguards to prevent this from happening have exploded in the last few years, both from billionaire-funded nonprofits like the Center for AI Safety and companies like Anthropic. A lot of researchers disagree with that premise—'human extinction seems to be very very unlikely,' New York University professor emeritus Gary Marcus, who studies the intersection of psychology and AI, told Forbes . 'But working on AI safety is noble, and very little current work has provided answers.' Now, the field of AI safety and its promise to prevent the worst effects of AI is motivating young people to drop out of school. 'If your career is about to be automated by the end of the decade, then every year spent in college is one year subtracted from your short career.' Nikola Jurković Physics and computer science major Adam Kaufman left Harvard University last fall to work full-time at Redwood Research, a nonprofit examining deceptive AI systems that could act against human interests. 'I'm quite worried about the risks and think that the most important thing to work on is mitigating them,' said Kaufman. 'Somewhat more selfishly, I just think it's really interesting. I work with the smartest people I've ever met on super important problems.' He's not alone. His brother, roommate and girlfriend have also taken leave from Harvard for similar reasons. The three of them currently work for OpenAI. Other students are terrified of AGI, but less because it could destroy the human race and more because it could wreck their career before it's even begun. Half of 326 Harvard students surveyed by the school's undergraduate association and AI safety club were worried about AI's impact on their job prospects. 'If your career is about to be automated by the end of the decade, then every year spent in college is one year subtracted from your short career,' said Nikola Jurković, who graduated from Harvard this May and served as the AI safety group's AGI preparedness lead. 'I personally think AGI is maybe four years away and full automation of the economy is maybe five or six years away.' Already, some companies are hiring fewer interns and recent graduates because AI is capable of doing their tasks. Others are conducting mass layoffs. Anthropic CEO Dario Amodei has warned that AI could eliminate half of all entry-level white-collar jobs and cause unemployment to rise to 20% in the next few years. Students are terrified that this shift will dramatically accelerate when true AGI arrives, though when that might happen is up for debate. OpenAI CEO Sam Altman thinks AGI will be developed before 2029, while Google DeepMind CEO Demis Hassabis predicts that it'll come in the next five to 10 years. Jurković believes it might arrive even sooner: He co-authored a timeline forecast for the AI Futures Project, which also predicts the ability to automate most white-collar jobs by 2027. Others disagree: 'It is extremely unlikely that AGI will come in the next five years,' Marcus said. 'It's just marketing hype to pretend otherwise when so many core problems (like hallucinations and reasoning errors) remain unsolved.' Marcus has noted that throwing more and more data and computing power at AI models has so far failed to produce models sophisticated enough to do many of the same kinds of tasks as humans. While questions remain about when AGI will occur and how valuable a college degree will be in a world upended by human-level artificial intelligence, students are itching to pursue their careers now, before, they worry, it's too late. That's led many to drop out to start their own companies. Since 2023, students have been leaving college to chase the AI gold rush, drawn to the success stories of generations past like Altman and Meta CEO Mark Zuckerberg. Anysphere CEO Michael Truell, now 24, and Mercor CEO Brendan Foody, 22, dropped out of MIT and Georgetown University respectively to pursue their startups. Anysphere was last valued at $9.9 billion, while Mercor has raised over $100 million. With AGI threatening to completely replace human labor, some students see a ticking clock—and a huge opportunity. 'I felt that there's a limited window to act in order to have a hand on the steering wheel,' said Jared Mantell, who was studying economics and computer science at Washington University in St. Louis before dropping out to focus full-time on his startup dashCrystal, which aims to automate design of electronics. The company has raised over $800,000 so far at a valuation of around $20 million. Dropping out means losing out on the benefits of a college degree. According to the Pew Research Center, younger adults with a bachelor's degree or more generally make at least $20,000 more than their peers without one. And in a world where entry-level jobs are being decimated by AI, lacking a degree could limit job prospects for young people even more. Even the cofounder of Y Combinator, a startup accelerator known for funding young founders who have dropped out, thinks students should stay in school. 'Don't drop out of college to start or work for a startup,' Paul Graham posted on X in July. 'There will be other (and probably better) startup opportunities, but you can't get your college years back.' Blair doesn't think that dropping out of school is for everyone. 'It's very difficult and taxing to drop out of college early and get a job,' she said. 'This is something that I would only recommend to extremely resilient individuals who felt they have been adequately prepared to get a job by college already.' More from Forbes Forbes You're Not Imagining It: AI Is Already Taking Tech Jobs By Richard Nieva Forbes How Small Business Can Survive Google's AI Overview By Brandon Kochkodin Forbes How Scrubbing Your Social Media Could Backfire–And Even Hurt Your Job Prospects By Maria Gracia Santillana Linares Forbes Vibe Coding Turned This Swedish AI Unicorn Into The Fastest Growing Software Startup Ever By Iain Martin

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store